Literature DB >> 2903481

Persistent human immunodeficiency virus type 1 antigenemia in children correlates with disease progression.

L G Epstein1, C A Boucher, S H Morrison, E M Connor, J M Oleske, J M Lange, J van der Noordaa, M Bakker, J Dekker, H Scherpbier.   

Abstract

In a longitudinal study, human immunodeficiency virus type 1 (HIV-1) antigen (HIV-Ag) was measured in serum specimens from 54 children with HIV-1 infection followed for a median duration of 17 months. The persistent detection of free HIV-Ag in a group of 25 children was associated with clinical deterioration in 22 (88%) and a mortality of 52%, whereas the persistent nondetection of free HIV-Ag in a group of 18 children was associated with clinical deterioration in five (28%) and a mortality of 11% during the period of observation. Nine children had transient HIV-1 antigenemia and two children converted from HIV-Ag negative to positive during the study. Free HIV-Ag levels varied inversely with antibody reactivity to viral core proteins p24 and p17 determined by Western immunoblot, suggesting either the formation of immune complexes or a balance between viral expression and the host immune response. Five mother-infant pairs were studied for HIV-Ag expression in the perinatal period. In three of these pairs, both mother and infant were HIV-Ag negative, in one pair the mother had high levels of HIV-Ag and the infant was HIV-Ag negative. In the remaining mother-infant pair, the neonate became HIV-Ag positive but the mother was HIV-Ag negative prepartum and postpartum. These data suggest that HIV-Ag probably does not cross the placenta and that the detection of free HIV-Ag in the offspring of a HIV-1 infected mother most likely indicates viral infection.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2903481

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

1.  HIV infection in children.

Authors:  J Mok
Journal:  BMJ       Date:  1991-04-20

2.  Antibody response to human immunodeficiency virus type 1 protease according to risk group and disease stage.

Authors:  C A Boucher; M H de Jager; C Debouck; L G Epstein; F de Wolf; T F Wolfs; J Goudsmit
Journal:  J Clin Microbiol       Date:  1989-07       Impact factor: 5.948

3.  Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.

Authors:  K K van Rompay; P J Dailey; R P Tarara; D R Canfield; N L Aguirre; J M Cherrington; P D Lamy; N Bischofberger; N C Pedersen; M L Marthas
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

4.  Correlation of serum antigen and antibody concentration with clinical features in HIV infection.

Authors:  M Ellaurie; A Rubinstein
Journal:  Arch Dis Child       Date:  1991-02       Impact factor: 3.791

5.  Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS.

Authors:  K K Van Rompay; M G Otsyula; M L Marthas; C J Miller; M B McChesney; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

6.  Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques.

Authors:  M L Marthas; K K van Rompay; M Otsyula; C J Miller; D R Canfield; N C Pedersen; M B McChesney
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

Review 7.  Laboratory methods for early detection of human immunodeficiency virus type 1 in newborns and infants.

Authors:  A V Sison; J M Campos
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.